User login
Key clinical point: Patients with multimorbid psoriasis should be monitored for the potential development of psoriatic arthritis (PsA) as the presence of ≥2 morbidities at psoriasis incidence has been associated with an increased risk for PsA.
Major finding: The cumulative incidence of PsA in patients with psoriasis was 1.7%, 2.5%, and 2.9% at 5, 10, and 15 years after psoriasis incidence, respectively, with the risk for PsA being higher in those with ≥2 morbidities (hazard ratio 2.46; 95% CI 1.01-6.01).
Study details: Findings are from a retrospective cohort study including 817 patients with incident psoriasis and 849 age- and sex-matched comparator individuals without psoriasis; of these, 23 patients with psoriasis developed PsA during a median follow-up of 13.3 years.
Disclosures: This study was sponsored by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and other sources. Two authors declared serving as consultants for or receiving research support and grants from various sources.
Source: Karmacharya P, Chakradhar R, Hulshizer CA, et al. Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: A population-based study. Rheumatology (Oxford). 2024 (Jan 30). doi: 10.1093/rheumatology/keae040 Source
Key clinical point: Patients with multimorbid psoriasis should be monitored for the potential development of psoriatic arthritis (PsA) as the presence of ≥2 morbidities at psoriasis incidence has been associated with an increased risk for PsA.
Major finding: The cumulative incidence of PsA in patients with psoriasis was 1.7%, 2.5%, and 2.9% at 5, 10, and 15 years after psoriasis incidence, respectively, with the risk for PsA being higher in those with ≥2 morbidities (hazard ratio 2.46; 95% CI 1.01-6.01).
Study details: Findings are from a retrospective cohort study including 817 patients with incident psoriasis and 849 age- and sex-matched comparator individuals without psoriasis; of these, 23 patients with psoriasis developed PsA during a median follow-up of 13.3 years.
Disclosures: This study was sponsored by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and other sources. Two authors declared serving as consultants for or receiving research support and grants from various sources.
Source: Karmacharya P, Chakradhar R, Hulshizer CA, et al. Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: A population-based study. Rheumatology (Oxford). 2024 (Jan 30). doi: 10.1093/rheumatology/keae040 Source
Key clinical point: Patients with multimorbid psoriasis should be monitored for the potential development of psoriatic arthritis (PsA) as the presence of ≥2 morbidities at psoriasis incidence has been associated with an increased risk for PsA.
Major finding: The cumulative incidence of PsA in patients with psoriasis was 1.7%, 2.5%, and 2.9% at 5, 10, and 15 years after psoriasis incidence, respectively, with the risk for PsA being higher in those with ≥2 morbidities (hazard ratio 2.46; 95% CI 1.01-6.01).
Study details: Findings are from a retrospective cohort study including 817 patients with incident psoriasis and 849 age- and sex-matched comparator individuals without psoriasis; of these, 23 patients with psoriasis developed PsA during a median follow-up of 13.3 years.
Disclosures: This study was sponsored by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and other sources. Two authors declared serving as consultants for or receiving research support and grants from various sources.
Source: Karmacharya P, Chakradhar R, Hulshizer CA, et al. Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: A population-based study. Rheumatology (Oxford). 2024 (Jan 30). doi: 10.1093/rheumatology/keae040 Source